Atlas Trials

Study to Evaluate D2 Receptor Occupancy Following Single Intravenous Administration of ATI-9242

Clinical trial NCT02824666 · COMPLETED

Trial details

NCT number
NCT02824666
Sponsor
Braeburn Pharmaceuticals
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Schizophrenia
Start date
2016-06-20
Primary completion
2016-09-06
Enrollment
7

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.